HomeBody MapPeptidesCalculator
Catalog3 refs

Thymosin Alpha-1

Immune ModulationImmune System ModulatorImmuneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
~2 Hours
Half-life
35
Uses
1.5 mg
Typical
Body Map
Loading 3D model…
Overview

A 28-amino-acid peptide originally isolated from the thymus gland that works as an immune modulator rather than a stimulant. It signals through toll-like receptors (TLR9 and TLR2) on dendritic cells, pushing naive T cells toward a Th1 profile, boosting natural killer cell activity, and improving antibody responses. It can also promote regulatory T cells via the IDO pathway, restoring immune balance. Approved in 30+ countries as Zadaxin for chronic hepatitis B, but not FDA approved in the United States.

Primary Uses
Sepsis management
Chronic hepatitis B/C treatment
HIV immune reconstitution
Cancer immunotherapy support
Vaccine adjuvant applications
Immune support in immunocompromised states
Antiviral and immunomodulation research
Vaccine adjuvant studies
Oncology adjunct research
T-cell activation
Chronic hepatitis B treatment research
Severe COVID-19 treatment research
Sepsis treatment research
Chronic obstructive pulmonary disease (COPD) exacerbation research
Aging and immune function research
Primary immunodeficiencies (DiGeorge syndrome)
Vaccine enhancement
HIV/AIDS support
Cytokine reduction
Hepatitis B/C support
Autoimmune conditions
Post-surgical immune restoration
Exercise-induced immunosuppression
Thymic regeneration support
Immune senescence delay
Hepatitis B
Hepatitis C
Immunodeficiency research
Immune system modulation
Chronic hepatitis B treatment
Immune support and modulation
Chronic infections
Sepsis (studied but not proven effective in phase 3 trial)
Cancer add-on therapy
Vaccine response enhancement
Protocol Reference
Dose
1.5 mg
Frequency
2x Weekly
Half-life
~2 Hours
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 4; Russia Approved; 187 PubMed-Verified Studies / Well Studied / FDA-approved as Zadaxin for hepatitis B and C / Clinical Trials (disputed)
Research References· 21
Research Literature \- Observed in studies ↗
PubMedPMID 333629993.2 mg weekly
https://pubmed.ncbi.nlm.nih.gov/39814420/
PubMedPMID 39814420- [https://pmc.ncbi.nlm.nih.gov/articles/PMC4056079/](https://pmc.ncbi.nlm.nih.gov/articles/PMC4056079/)
Aging and Thymosin Alpha-1.↗
PubMedPMID 41373628Int J Mol Sci2025Simonova MA, Ivanov I, Shoshina NS, Komyakova AM, et al.
Research Models
HumanMouseRat
Also in Immune Modulation
Immune Modulation
Antimicrobial peptides (AMPs)
Therapeutic antimicrobial agents · Immune modulation
Immune Modulation
ARA-290
Nerve pain · Small fiber neuropathy
Immune Modulation
Arenicin-3
Multidrug-resistant infections · Hospital-acquired infections
Immune Modulation
Cathelicidin (LL-37)
Antimicrobial activity · Immune modulation
Compare